HOME >> BIOLOGY >> NEWS
New advances in thrombosis help further understanding of disease prevention

eemed to experience a higher incidence of major bleeding over that of standard therapy (0.7 percent - 25 mg bid; 4.1 percent - 50 mg bid; 3.5 percent - 75 mg bid; and 5.8 percent - 100 mg bid versus 0.0 percent - enoxaparin 30 mg bid). The three highest doses of razaxaban were stopped before the intended sample size of 150 patients was reached, due to increased reports of bleeding. In this study, the lowest dose of razaxaban, 25 mg bid, demonstrated potential for increased efficacy and similar safety compared to current standard treatment.

Randomized, Double-Blind Comparison of Ximelagatran, an Oral Direct Thrombin Inhibitor, and Warfarin to Prevent Venous Thromboembolism (VTE) after Total Knee Replacement (TKR): EXULT B (Abstract 39)

Total knee replacement surgery, like many other major orthopedic surgeries, continues to be hampered by venous thromboembolism events, such as deep vein thrombosis and pulmonary embolism. Without any preventive medication, harmful blood clots occur in two thirds of all total knee replacement surgery patients. Anticoagulants that are currently approved in the U.S. for prevention of venous thromboembolism are still associated with unacceptably high rates of deep vein thrombosis and require regular dosage monitoring to prevent major bleeding events.

"Oral anticoagulants that are currently available have many limitations. There is a great need for new therapies with increased safety and efficacy," said Charles Francis, M.D., of the University of Rochester, Rochester, N.Y., lead investigator of the study. "The results from this study encourage us to continue looking at ximelagatran as a preventive treatment for this serious complication in total knee replacement surgery."

The trial, led by Dr. Francis, compares the safety and efficacy of ximelagatran, a novel oral direct thrombin inhibitor, to warfarin for prevention of venous thromboembolism in total knee replacement patients.
'"/>

Contact: Aimee Frank
amf@spectrumscience.com
202-955-6222
American Society of Hematology
6-Dec-2003


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Grant advances biochemical engineering laboratory
2. Virginia Bioinformatics Institute researcher advances fight against sudden oak death disease
3. Undergraduate research experience advances education
4. UT Southwestern researchers cite recent advances in underlying causes of rare body-fat disorders
5. UCSF finding advances insight into adult stem cells in human brain
6. Federal grant supports advances in infant heart disease at Childrens Hospital of Philadelphia
7. Human embryonic stem cells may promise medical advances
8. Scientists making advances in cancer prevention, detection and treatment to receive awards
9. Conference to highlight medical advances resulting from 50 years of DNA knowledge
10. Annual bibliography of significant advances in dietary supplement research 2002
11. Dartmouth study advances prion disease research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December ... leading global financial services provider, today announced an agreement with ... behavioural biometrics, to join forces. The partnership will enable clients ... strategies in compliance with local data protection regulation. ... In order to ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... ... January 23, 2017 , ... CallTower is proud to ... Product of the Year Award winner for 2017. , For three consecutive years, ... solutions. In 2016, CallTower was awarded with the hosted VoIP Excellence award and in ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... endeavors to bring to market a pioneering medical device for the treatment of ... an engagement contract with Emergo, a global regulatory consultancy that helps companies like ...
(Date:1/21/2017)... Jan. 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... on the licensing, development and commercialization of innovative biopharmaceutical ... Best Company in North America ... award based on the FDA approval of three ... ENTYCE ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... YORK , January 20, 2017 ... current market conditions have influenced the most recent performances ... Therapeutics Inc. (NASDAQ: RGLS ), Abeona Therapeutics ... (NASDAQ: TBPH ), and Sage Therapeutics Inc. ... research report by Grand View Research, global Biotech market size is ...
Breaking Biology Technology:
Cached News: